Management of canine inflammatory bowel disease

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 20, Issue 3, 1998, Pages 317-331

  Marks, Stanley L ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMER COLL OF VET INT MEDICINE   (United States)

^d Amer Coll of Veterinary Nutrition   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

EID: 3042956692     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Guilford WG: Idiopathic inflammatory bowel diseases, in Guilford WG, Center SA, Strombeck DR (eds): Strombeck's Small Animal Gastroenterology, ed 3. Philadelphia, WB Saunders Co, 1996, pp 451-486.
2. 99mTc-diethylenetriaminopentaacetic acid in inflammatory bowel disease. Am J Gastroenterol 81:767-770, 1986.
3. Mayberry JF, Rhodes J, Heatley RV: Infections which cause ileocolic disease in animals: Are they relevant to Crohn's disease? Gastroenterology 78:1080-1084, 1980.
4. Belsheim MR, Darwish RZ, Watson WC, et al: Bacterial L-form isolation from inflammatory bowel disease patients. Gastroenterologe 85:364-369, 1983.
5. Giaffer MH, Cann P, Holdsworth CD: Long-term effects of elemental and exclusion diets for Crohn's disease. Aliment Pharmacol Ther 5:115-125, 1988.
6. Mansfield JC, Giaffer MH, Holdsworth CD: Controlled diet of oligopeptide versus amino acid diet in treatment of active Crohn's disease. Gut 36:60-66, 1995.
7. Batt RM, McLean L, Riley JE: Response of the jejunal mucosa of dogs with aerobic and anaerobic bacterial overgrowth to antibiotic therapy. Gut 29:473-482, 1988.
8. Sartor RB: Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis and experimental intestinal inflammation, in Kirsner JB, Shorter RG (eds): Inflammatory Bowel Disease. Baltimore, Williams & Wilkins, 1995, pp 96-124.
9. Nelson RW, Stookey LJ, Kazacos E: Nutritional management of idiopathic chronic colitis in the dog. J Vet Intern Med 2:133-137, 1988.
10. Rask-Madsen J: Eicosanoids and their role in the pathogenesis of diarrheal diseases. Clin Gastroenterol 15:545-566, 1986.
11. Jouet P, Sarna SK, Singaram C, et al: Immunocytes and abnormal gastrointestinal motor activity during ileitis in dogs. Am J Physiol 269:G913-G924, 1995.
12. Jouët P, Sarna SK: Platelet-activating factor (PAF) stimulates giant migrating contractions during ileal inflammation. J Phamacol Exp Therap 279:207-213, 1996.
13. Sethi AK, Sarna SK: Colonic motor activity in acute colitis in conscious dogs. Gastroenterology 100:954-963, 1991.
14. Sethi AK, Sarna SK: Colonic motor response to a meal in acute colitis. Gastroenterology 101:1537-1546, 1991.
15. 2+ channel blockade by verapamil inhibits GMCs and diarrhea during small intestinal inflammation. Am J Physiol 273:G785-G794, 1997.
16. Tams TR: Chronic canine lymphocytic plasmacytic enteritis. Compend Contin Educ Pract Vet 9(12):1184-1191, 1987.
17. Jergens AE, Moore FM, Haynes JS, et al: Idiopathic inflammatory bowel disease in dogs and cats: 84 cases (1987-1990). JAVMA 201:1603-1608, 1992.
18. Shimi A, Keghaui M, Borlurchi M: Salmonellosis in apparently healthy dogs. Vet Rec 98:110-111, 1976.
19. Wilcox B: Endoscopic biopsy interpretation in canine or feline enterocolitis. Semin Vet Med Surg 7:162-171, 1992.
20. Roth L, Walton AM, Leib MS, et al: A grading system for lymphocytic plasmacytic colitis in dogs. J Vet Diag Invest 2:257-262, 1990.
21. Roth L, Leib MS, Davenport DJ, et al: Comparisons between endoscopic and histologic evaluation of the gastrointestinal tract in dogs and cats: 75 cases (1984-1987). JAVMA 196:635-638, 1990.
22. Jacobs G, Collins-Kelly L, Lappin M, et al: Lymphocytic-plasmacytic enteritis in 24 dogs. J Vet Intern Med 4:45-53, 1990.
23. Couto CG, Rutgers HC, Sherding RG, et al: Gastrointestinal lymphoma in 20 dogs. J Vet Intern Med 3:73-78, 1989.
24. Lin HC, Doty JE, Reedy TJ, et al: Inhibition of gastric emptying by sodium oleate depends on length of intestine exposed by nutrient. Am J Physiol 259:G1031-G1036, 1990.
25. Meyer JH, Elashoff JD, Domeck M, et al: Control of canine gastric emptying of fat by lipolytic products. Am J Physiol 266:G1017-G1035, 1994.
26. Hofmann AF, Poley JR: Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long-chain triglyceride by medium-chain triglyceride. Gastroenterology 62:918-934, 1972.
27. Cummings JH, Wiggins HS, Jenkins DJA, et al: Influence of diets high and low in animal fat on bowel habit, gastrointestinal transit time, fecal microflora, bile acid, and fat excretion. J Clin Invest 61:953-963, 1978.
28. Leib MS, Hiler LA, Thatcher C, et al: Plasmacytic lymphocytic colitis in the dog. Semin Vet Med Surg 4:241-246, 1989.
29. Simpson JW, Maskell IE, Markwell PJ: Use of a restricted antigen diet in the management of idiopathic canine colitis. J Small Anim Pract 35:233-238, 1994.
30. Willard MD: Dietary therapy in large intestinal diseases. Proc 6th ACVIM Proc:713, 1988.
31. Eastwood MA: The physiological effect of dietary fiber. An update. Ann Rev Nutr 12:19-35, 1992.
32. Burrows CF, Kronfeld DS, Banta CA, et al: Effects of fiber on digestibility and transit time in dogs. J Nutr 112: 1726-1732, 1982.
33. Burrows CF, Merritt AM: Influence of alpha-cellulose on myoelectric activity of the proximal canine colon. Am J Physiol 245:G301-G306, 1983.
34. Leib MS, Monroe WE, Codner EC: Management of chronic large bowel diarrhea in dogs. Vet Med 86:922-929, 1991.
35. Hallman JE, Moxley RA, Reinhart GA, et al: Cellulose, beet pulp, and pectin/gum arabic effects on canine colonic microstructure and histopathology. Vet Clin Nutr 2:137-142, 1995.
36. Brockett M, Tanner GW: Dietary influence on microbial activities in the cecum of mice. Can J Microbiol 28:493-499, 1982.
37. Hawthorne AB, Edwards T, Filopowicz B, et al: Fish oil modifies neutrophil (PMN) function in ulcerative colitis. Gut 30:A738, 1989.
38. Scheurlen M, Dais W, Steinhilber D, et al: Effects of long-term application of fish oil on patients with Crohn's disease. Scand J Gastroenterol 24:(Suppl 158):100-101, 1989.
39. Hawthorne AB, Daneshmend TK, Hawkey CJ, et al: Treatment of ulcerative colitis with fish oil supplementation: A prospective 12-month randomized controlled trial. Gut 33: 922-928, 1992.
40. Vaughn DM, Reinhart GA, Swaim SF, et al: Evaluation of effects of dietary n-6 to n-3 fatty acid ratios on leukotriene B synthesis in dog skin and neutrophils. Vet Derm 5(4):163, 1994.
41. Summers RW, Switz DM, Sessions JT, et al: National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 77:847-869, 1979.
42. Binder HJ, Sandle GI: Electrolyte absorption and secretion in the mammalian colon, in Johnson LR (ed): Physiology of the Gastrointestinal Tract. New York, Raven Press, 1987, pp 1389-1419.
43. Scott J: Physiological, pharmacological and pathological actions of glucocorticoids on the digestive system. Clin Gastroenterol 10:627-652, 1981.
44. Flower RJ: Lipocortin and the mechanism of action of the glucocorticoids. Br J Pharmacol 94:987-1015, 1988.
45. Lauritsen K, Laursen LS, Bukhave K, et al: In vivo effects of orally administered prednisolone on prostaglandin and leukotriene production in ulcerative colitis. Gut 28:1095-1099, 1987.
46. Munck A, Mendel DB, Smith LS, et al: Glucocorticoids receptors and actions. Am Rev Respir Dis 141:S2-S10, 1990.
47. Richter KP: Lymphocytic-plasmacytic enterocolitis in dogs. Semin Vet Med Surg 7:134-144, 1992.
48. Dahlberg E, Thalen A, Brattsand R, et al: Correlation between chemical structure, receptor binding, and biological activity in some novel, highly active, 16 alpha, 17 alpha-acetyl-substituted glucocorticoids. Molec Pharmacol 25:70-78, 1984.
49. Greenberg GR, Feagan BG, Martin F, et al: Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 110:45-51, 1996.
50. Greenberg GR, Feagan BG, Martin F, et al: Oral budesonide for active Crohn's disease. N Engl J Med 331:836-841, 1994.
51. Rutgeerts P, Lofberg R, Malchow H, et al: A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331:842-845, 1994.
52. Halpern Z, Sold O, Baratz M, et al: A controlled trial of beclomethasone versus betamethasone enemas in distal ulcerative colitis. J Clin Gastroenterol 13:38-41, 1991.
53. Mulder CJJ, Tytgat GNJ: Topical corticosteroids in inflammatory bowel disease. Aliment Pharmacol Ther 7:125-130, 1993.
54. Tams TR: Feline inflammatory bowel disease. Vet Clin North Am Small Anim Pract 23:569-586, 1993.
55. Brogan M, Hiserodt J, Oliver M, et al: The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease. J Clin Immunol 5:204-211, 1985.
56. Rosenberg JL, Levin B, Wall AJ, et al: A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis Sci 20: 721-726, 1975.
57. Kirk AP, Lennard-Jones JE: Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 284:1291-1292, 1982.
58. Jewell DP, Truelove SC: Azathioprine in ulcerative colitis: Final report on a controlled therapeutic trial. Br Med J 4:627-630, 1974.
59. Zimmer JF, Burrington DB: Comparison of four protocols for treatment of canine giardiasis. JAAHA 22:168-172, 1986.
60. Grove DI, Mahmoud AAF, Warren KS: Suppression of cell-mediated immunity by metronidazole. Int Arch Allerg Appl Immunol 5:422-427, 1977.
61. Khilnani G, Rubin P, Present DH: Peripheral neuropathy in Crohn's disease patients treated with metronidazole: Who develops it? How long does it last? Gastroenterology 98:A660, 1990.
62. Dow SW, LeCouteur RA, Poss ML, et al: Central nervous system toxicosis associated with metronidazole treatment of dogs: Five cases (1984-1987). JAVMA 195:365-368, 1989.
63. Van Kruiningen HJ: Clinical efficacy of tylosin in canine inflammatory bowel disease. JAAHA 12:498-501, 1976.
64. Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety in sulphasalazine. Lancet 2:892-895, 1977.
65. Mahida YR, Lamming CE, Gallagher A, et al: 5-aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 32:50-54, 1991.
66. Crotty B, Rosenberg WMC, Aronson JK, et al: Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease. Gut 33:1353-1357, 1992.
67. Peskar BM, Dreyling KW, Peskar BA, et al: Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: Inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions 18:381-383, 1986.
68. Morgan RV, Bachrach A: Keratoconjunctivitis sicca associated with sulfonamide therapy in dogs. JAVMA 180:432-434, 1982.
69. Sansom J, Barnett KC, Long RD: Keratoconjunctivitis sicca in the dog associated with the administration of salicylazosulphapyridine (sulphasalazine). Vet Rec 116:391-393, 1985.
70. Barnett KC, Joseph EC: Keratoconjunctivitis sicca in the dog following 5-aminosalicylic acid administration. Hum Toxicol 6:377-383, 1987.
71. Dixon RAF, Diehl RE, Opas E, et al: Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343:282-284, 1990.
72. Laursen SL, Naesdal J, Bukhave K, et al: Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 335:683-685, 1990.
73. Peppercorn M, Days K, Elson C, et al: Zileuton, a 5-lipoxygenase inhibitor, in the treatment of active ulcerative colitis. Gastroenterology 106:A751, 1994.
74. Kahan BD: Cyclosporine. N Engl J Med 321(25):1725-1738, 1989.
75. Lichtiger S, Present DH: Preliminary report: Cyclosporine in treatment of severe active ulcerative colitis. Lancet 336: 16-19, 1990.
76. Brynskov J, Freund L, Rasmussen SN, et al: A placebo-controlled double-blind randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 321: 845-850, 1989.
77. Cronstein BN, Naime D, Ostad E: The anti-inflammatory mechanism of methotrexate-increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92:2675-2682, 1993.
78. Kozarek RA, Patterson DJ, Gelfand MD, et al: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 110: 353-356, 1989.